文献速递主动脉疾病

肾素血管紧张素系统阻断联合二甲双胍对糖尿病患者腹主动脉瘤增长率的协同影响:倾向匹配回顾性队列研究

The Combined Effect of Renin Angiotensin System Blockade and Metformin on Abdominal Aortic Aneurysm Growth Rate in People with Diabetes Mellitus-A Propensity-Matched Retrospective Cohort Study.
PubMed 文献 · Ann Vasc Surg · 2026-03-27

该回顾性队列研究纳入986例腹主动脉瘤监测患者(84.7%男性,199例2型糖尿病),评估二甲双胍与ACEI/ARB对AAA增长的影响。结果显示二甲双胍和ACEI/ARB独立关联于AAA增长率降低,联合治疗降低幅度最大,且在1:1倾向评分匹配后结果仍显著。

要点

  • 二甲双胍与ACEI/ARB均独立关联于AAA增长率降低
  • 联合治疗对AAA增长率降低幅度最大
  • 倾向评分匹配后上述关联仍显著

核心结论

  • 二甲双胍和ACEI/ARB治疗与AAA增长率降低相关,联合治疗保护效应最大。

研究设计与样本

  • 回顾性队列研究,纳入诺福克与诺维奇大学医院NHS信托基金会AAA筛查与监测项目全部患者,共986例(84.7%男性),其中199例2型糖尿病,并进行1:1倾向评分匹配验证。

主要发现

  • 2型糖尿病组平均AAA增长率显著低于非糖尿病组(2.2 mm/年[SD 3.1] vs. 2.7 mm/年[SD 2.9];P=0.042)。
  • 2型糖尿病组平均随访时间更长(5.2年[SD 3.6] vs. 4.6年[SD 3.3];P=0.03)。
  • 二甲双胍和ACEI/ARB使用分别独立关联于AAA增长率降低(1.40 mm/年,95%CI 1.05-1.88;1.67 mm/年,95%CI 1.52-1.83)。
  • 联合治疗与最大降低相关(1.19 mm/年,95%CI 0.97-1.47),相比两者均未使用者(1.94 mm/年,95%CI 1.78-2.12)。
  • 上述发现在1:1倾向评分匹配后仍显著。

关键数值与推荐

  • 2型糖尿病组初始AAA平均直径与非糖尿病组无显著差异(39.3 mm[SD 7.2] vs. 39.4 mm[SD 6.9];P=0.68)。

临床怎么用

  • 对于合并2型糖尿病的AAA患者,可考虑二甲双胍与ACEI/ARB联合治疗以延缓AAA增长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identification of a safe and effective medical therapy for abdominal aortic aneurysm (AAA) remains a significant unmet clinical need. This study evaluated the associations between commonly prescribed medications in type 2 diabetes mellitus (T2DM), HbA1c measurements, and AAA growth over a 14-year surveillance period. METHODS: A retrospective cohort study including all patients enrolled in the AAA screening and surveillance program at Norfolk and Norwich University Hospital NHS Foundation Trust. Records of AAA size, risk factors, medications, outcomes, complications, and mortality were analyzed. A 1:1 propensity matching was undertaken to validate results. RESULTS: The study comprised 986 patients (84.7% male), of whom 199 had T2DM. The mean initial AAA diameter did not differ significantly between groups (39.3 mm [standard deviation (SD) 7.2] in T2DM versus 39.4 mm [SD 6.9] in non-T2DM; P = 0.68). Patients with T2DM had a significantly lower mean AAA growth rate (2.2 mm/year [SD 3.1] vs. 2.7 mm/year [SD 2.9]; P = 0.042). The mean follow-up duration was longer in the T2DM group (5.2 years [SD 3.6] vs. 4.6 years [SD 3.3]; P = 0.03). Use of metformin and angiotensin-converting enzyme inhibitor/angiotensin II receptor type I blocker therapy was independently associated with reduced AAA growth rates (1.40 mm/year, 95% confidence interval [CI] 1.05-1.88; and 1.67 mm/year, 95% CI 1.52-1.83, respectively). Combined therapy was associated with the greatest reduction (1.19 mm/year, 95% CI 0.97-1.47) compared with neither medication (1.94 mm/year, 95% CI 1.78-2.12). These findings remained significant after 1:1 propensity score matching. CONCLUSION: Metformin and ACEi/angiotensin II receptor type I blocker therapy are associated with reduced AAA growth rates, with the greatest protective effect observed in patients receiving combined therapy.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Otify EAAA, Nunney I, Dhatariya K, et al. The Combined Effect of Renin Angiotensin System Blockade and Metformin on Abdominal Aortic Aneurysm Growth Rate in People with Diabetes Mellitus-A Propensity-Matched Retrospective Cohort Study. Ann Vasc Surg. 2026. PMID: 41905460. doi:10.1016/j.avsg.2026.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。